Longevity & AgingTriple Agonist Retatrutide Achieves 18.8% Weight Loss in Type 2 Diabetes Trial
Retatrutide, an investigational drug targeting three hormone pathways — GLP-1, GIP, and glucagon — produced up to 18.8% body weight loss in adults with obesity and type 2 diabetes in a major phase III trial. Published in The Lancet and presented at the EASD annual meeting, the TRIUMPH-2 trial enrolled 1,152 participants over 80 weeks. The highest dose also reduced HbA1c by 1.45 percentage points and cut triglycerides by 35.6%, high-sensitivity C-reactive protein by 56.1%, and waist circumference by over 15 cm. These results surpass what semaglutide and tirzepatide have achieved in diabetic populations, suggesting that engaging all three hormone systems simultaneously may unlock greater metabolic benefit for people who historically lose less weight than those without diabetes.
